Apotex Health Corp.
APTX.TO
Toronto Stock Exchange38.00
CAD
+0.31
- -
ISIN
CA03772D1015
CUSIP
03772D101
Return %
Stock
S&P500
1Y
40.74
20.63
3Y
40.74
71.71
5Y
40.74
72.73
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jeff Watson
- Full Time Employees
- 6,216
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 150 Signet Drive Toronto ON Canada M9L 1T9
- IPO Date
- Jun 11, 2026
- Website
- apotex.com
- Similar Companies
- Business
- Apotex Health Corp. is a fully integrated pharmaceutical healthcare company engaged in the development, manufacture, and commercialization of prescription medicines, over-the-counter products, and health-related consumer goods, with a focus on innovative therapies and access programs across global markets. The company operates through a diversified portfolio spanning branded and generic pharmaceuticals, biologics, and specialty products, supported by research and development, manufacturing, distribution, and regulatory compliance capabilities. Apotex Health Corp. maintains a vertically integrated operating model that includes active pharmaceutical ingredient (API) production, formulation development, finished dosage manufacturing, packaging, quality control, and global distribution networks. Founding year and headquarters - Founded in 1978 - Headquarters located in Toronto, Ontario, Canada Geographic footprint and subsidiaries - Geographic operations span North America, Europe, Asia, and emerging markets, with manufacturing facilities and regional offices across Canada, the United States, Europe, and Asia - Maintains subsidiaries and affiliates in multiple jurisdictions to support regulatory approvals, manufacturing, and commercial activities Core products and services (main products and services) - Prescription medicines: branded pharmaceutical products across therapeutic areas including oncology, immunology, infectious diseases, neurology, and cardiovasculars - Generic medicines: a broad portfolio of high-quality generics spanning multiple therapeutic classes for global markets - Biologics and biosimilars: biologic therapies and biosimilar products aimed at expanding patient access to essential biologics - Over-the-counter and consumer health products: non-prescription formulations and wellness products distributed through retail and healthcare channels - API and contract development/manufacturing: active pharmaceutical ingredients production and contract development/manufacturing services for third parties - Research and development: early-stage and late-stage clinical development, formulation science, and process optimization - Regulatory and quality services: regulatory affairs support, quality assurance, pharmacovigilance, and compliance management - Packaging, distribution, and supply chain services: finished product packaging, serialization, logistics, and broad distribution capabilities to global markets - Patient access and assistance programs: pricing, reimbursement navigation, patient support, and access programs to improve affordability and uptake Latest major company changes - Strategic alliances and partnerships: enters collaborations with global healthcare and pharmaceutical partners to co-develop and co-commercialize therapies, expand geographic reach, and optimize supply chains - Funding rounds and acquisitions: engages in selective acquisitions and strategic investments to bolster manufacturing capacity, diversify the product portfolio, and accelerate pipeline development - New product launches and service offerings: launches novel therapies and expands indications across key therapeutic areas; introduces new specialized manufacturing services and digital patient support platforms - Corporate restructurings and strategic shifts: reorganizations to optimize global operations, streamline R&D pipelines, and enhance manufacturing capacity for high-demand therapies - Operational changes: expands manufacturing footprint with new facilities or expansions, and implements advanced quality systems and regulatory compliance enhancements to accelerate time-to-market Industry context and segments - Industry: Pharmaceutical manufacturing and healthcare products - Segments: Branded pharmaceuticals, generics, biologics and biosimilars, consumer health, contract development and manufacturing, API production, and supply chain services Target markets and customers - Hospitals, clinics, specialty pharmacies, and large retail distributors - Pharmaceutical and biotechnology companies requiring contract development/manufacturing and API supply - Regulators and national health systems through pricing and reimbursement programs - Patients and caregivers via patient assistance and education initiatives Parent and subsidiaries - Operates as a stand-alone corporate entity with potential affiliates and wholly owned subsidiaries supporting regional operations and product lines - Maintains relationships with external contract manufacturers and suppliers to ensure scale and resilience Notes - The description reflects Apotex Health Corp. as a prominent player in global pharmaceutical manufacturing and healthcare products, articulating core products, services, geographic reach, and recent strategic movements in alignment with financial data provider-style profiles - For precise, up-to-date details on specific product brands, exact geographic listings, and the latest corporate actions, consult the company’s official disclosures and filings and recent announcements from Apotex Health Corp.